| Description | This product is a human monoclonal antibody that reacts with CD22. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Immunogen | Human tonsil lymphocytes. |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; IF; IP; Neut; FuncS; ELISA; FC; ICC |
| Application Notes | The antibody is recommended for detection of CD22 by IF, IP, Neut, FuncS, ELISA, FC, ICC assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CD22 |
| Alternative Name | CD22; CD22 molecule; CD22 antigen; B-cell receptor CD22; sialic acid binding Ig like lectin 2; SIGLEC 2; SIGLEC2; BL-CAM; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding |
| Gene ID | 933 |
| UniProt | P20273 |
| Related pathway | Hematopoietic Stem Cell Differentiation Pathways; Lineage-specific Markers; Innate Immune System |
| Research Area | Immunology; Cancer Research |
Figure 1 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in SDS-PAGE
SDS-PAGE analysis of V3S-0622-YC4309 in non-reduced and β-mercaptoethanol-reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as about 180 kDa.
Figure 1 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in SDS-PAGE
Figure 2 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in SEC-HPLC
The purity of V3S-0622-YC4309 was greater than 99% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.3
Detection: UV 280 nm
Injection: 25 µl
Figure 2 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in SEC-HPLC
Figure 3 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in ELISA
ELISA analysis of V3S-0622-YC4309 was performed by coating with Recombinant Human CD22 Protein. Then blocked with BSA, and incubated with Anti-Human CD22 Antibody (V3S-0622-YC4309). The HRP-conjugated anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in ELISA
Figure 4 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in WB
Western blot analysis of V3S-0622-YC4309 was performed by loading Recombinant Human CD22 Protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4309 and HRP Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)
Figure 4 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in WB
